-
Aug 11, 2024 | 
nature.com | Rajshekhar Chakraborty |Aniko Szabo |Carolina Schinke |Binod Dhakal |Ghulam Rehman Mohyuddin |Martin Kaiser | +1 more
To the Editor:Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57–71% [1,2,3,4,5,6].
-
Aug 4, 2024 | 
nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more
AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.
-
Jun 28, 2024 | 
cco.amegroups.org | Carolina Schinke
Have a website account?Log In orRegister for exclusive website content. Home / Vol 13, No 3 (June 30, 2024) / The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells i... PDF 478 views Full Text 1 views Peer Review File 80 views COI Form 106 views
-
Apr 14, 2024 | 
onlinelibrary.wiley.com | Meera Mohan |Carolina Schinke |Ashby TC
As clinical outcomes and therapeutic options in multiple myeloma (MM) continue to improve, there is a growing interest in stratifying newly diagnosed MM patients to further tailor treatment based on disease risk.
-
Dec 14, 2023 | 
cancernetwork.com | Carolina Schinke |Joselle M. Cook |Luciano Costa |Binod Dhakal
2 Clarke Drive Cranbury, NJ 08512
-
Nov 20, 2023 | 
cancernetwork.com | Carolina Schinke |Joselle M. Cook |Luciano Costa |Binod Dhakal
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
-
Nov 9, 2023 | 
cancernetwork.com | Carolina Schinke |Joselle M. Cook |Luciano Costa |Binod Dhakal
2 Clarke Drive Cranbury, NJ 08512
-
Nov 2, 2023 | 
cancernetwork.com | Carolina Schinke |Joselle M. Cook |Luciano Costa |Binod Dhakal
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
-
Aug 21, 2023 | 
onclive.com | Carolina Schinke
Carolina D. Schinke, MD, associate professor, medicine, Myeloma Center, University of Arkansas for Medical Sciences, discusses the safety profile of talquetamab-tgvs (Talvey) in the phase 1/2 MonumenTAL-1 trial (NCT04634552) of patients with relapsed/refractory multiple myeloma. The MonumenTAL-1 trial evaluated the safety and efficacy of the first-in-class, GPRC5D-targeted bispecific antibody talquetamab in patients with treatment-naïve or relapsed/refractory multiple myeloma.
-
Aug 16, 2023 | 
onclive.com | Carolina Schinke
Carolina D. Schinke, MD, associate professor, medicine, Myeloma Center, University of Arkansas for Medical Sciences, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial (NCT04634552) in patients with multiple myeloma. Patients who have received several previous treatments for relapsed/refractory multiple myeloma have an unmet need that should be addressed, Schinke begins, stating that few treatment options exist for this population.
